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Epidemiological studies have demonstrated the importance of cardiovascular diseases in
Western countries. Among the cell types associated with a dysfunctional vasculature,
smooth muscle (SM) cells are believed to play an essential role in the development
of these illnesses. Vascular SM cells are key regulators of the vascular tone and
also have an important function in the development of atherosclerosis and restenosis.
While in the normal vasculature, contractile SM cells are predominant, in atherosclerotic
vascular lesions, synthetic cells migrate toward the neointima, proliferate, and synthetize
extracellular matrix proteins. In the present study, we have examined the role of caveolin-
3 in the regulation of SM cell phenotype. Caveolin-3 is expressed in vivo in normal arterial
SM cells, but its expression appears to be lost in cultured SM cells. Our data show that
caveolin-3 expression in the A7r5 SM cell line is associated with increased expression
of contractility markers such as SM α-actin, SM myosin heavy chain but decreased
expression of the synthetic phenotype markers such as p-Elk and Klf4. Moreover, we
also show that caveolin-3 expression can reduce proliferation upon treatment with LDL
or PDGF. Finally, we show that caveolin-3-expressing SM cells are less sensitive to
apoptosis than control cells upon treatment with oxidized LDL. Taken together, our data
suggest that caveolin-3 can regulate the phenotypic switch between contractile and
synthetic SM cells. A better understanding of the factors regulating caveolin-3 expression
and function in this cell type will permit the development of a better comprehension of the
factors regulating SM function in atherosclerosis and restenosis.
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Introduction
The development of atherosclerosis is characterized by vascular wall accumulation of lipids,
which can attract monocyte-derived macrophages followed by vascular smooth muscle cells
(vSMC). Migrating and proliferating (i.e., intimal) SM cells have specific properties not nor-
mally observed in medial SM cells. These newly acquired properties include the ability of these
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cells to produce extracellular matrix proteins and a reduction
in the expression of proteins involved in muscle contraction.
These cells have been linked to a synthetic phenotype whereas
medial SMcells have been associatedwith a contractile phenotype.
Contractile cells are characterized by the expression of contractile
proteins (such as calponin and SMα-actin). By contrast, synthetic
cells are described with a reduced expression of contractile pro-
teins and an increased expression of proteins involved in migra-
tion/invasion and proliferation as well as extracellular matrix
protein production. Therefore, a synthetic phenotype is normally
observed during embryonic differentiation of vessels while in the
adult healthy vasculature, vSMCs normally present a contractile
phenotype that regulates blood pressure and flow (1). However,
during the development of diseases such as atherosclerosis and
restenosis (2–4), the migration of vSMC from the media to the
intima in response to the inflammatory milieu induces a switch
from a contractile to a synthetic phenotype. One of the main
transcription factors that regulates the vSMC phenotype is serum
response factor (SRF) (5). SRF activity is finely regulated by co-
transcription factors Elk-1 and myocardin (6, 7). For example,
previous studies have demonstrated that phosphorylated Elk-1
(p-Elk-1) can repress the transcription of vSMC-specific genes
such as SM 22α (7). By contrast, the myocardin/SRF complex
upregulates key proteins that favor contractility: they include SM
22α, SMmyosin heavy chain, and SM α-actin (8–11). In addition,
Krüppel-like transcription factor 4 (Klf-4), a known repressor of
vSMC contractile marker genes, has also been shown to induce a
phenotypic switch toward the vSMC synthetic state (8, 12).
Caveolae are flask-shaped structures present at the plasma
membrane. Caveolins were identified as essential proteins to form
this invagination. Currently, three protein members of this family
have been identified, and they are named caveolin-1, -2, and -
3. Both caveolin-1 and -3 can induce caveolae formation while
caveolin-2 requires caveolin-1 to reach the plasma membrane
(13). Among them, caveolin-3 expression is restricted to mus-
cle cells (14). In particular, vSMCs express all of the caveolin
isoforms, which can interact with each other to form homo- or
hetero-oligomers (15). In addition, studies in Cav-1- and Cav-3-
deficient mice have indicated that caveolin-1 is responsible for
the formation of the majority of caveolae in SMCs (15), sug-
gesting that caveolin-3 may have an unidentified role in this cell
type. While caveolin-1 has been implicated in the regulation of
important signaling pathways, a similar role for caveolin-3 has
been proposed. Caveolin-3 is expressed in cardiac, skeletal, and
SM cells (14, 16). However, whereas fully differentiated cardiac
and skeletal muscle cells express only the caveolin-3 isoform,
vascular SM cells co-express either caveolin-1 and -2 (in veins) or
caveolin-1, -2, and -3 (in arteries) (17). This observation suggests
that, in arteries, caveolin-1 and -3 are co-expressed or that there
are different sub-populations of SM cells, which express different
caveolin proteins. Such heterogeneity of arterial smooth cells has
previously been reported with other protein markers (18). It also
appears that primary cultures of late passage arterial SMCs express
only caveolin-1 and -2 but lack caveolin-3 (19). Interestingly,
the proliferating primary cultured vSMCs present a phenotype
(synthetic phenotype, as opposed to the contractile phenotype
found in normal artery) that is similar to that of proliferating
vSMCs found in atherosclerotic lesions (20). These observations
may suggest that a change in the expression of caveolins occurs in
atherosclerotic lesions and in cell cultures.
To better understand the role of caveolin-3 in the regulation of
SM cell differentiation, we have examined its role in the regula-
tion of SM cell proliferation, migration, and contractile proper-
ties. Our data suggest that caveolin-3 directly regulates a switch
between proliferative and contractile vSMCs, and that regulating
its expressionmay also lead to a better understanding of the factors
regulating vascular function.
Materials and Methods
Reagents
Matrigel invasion chambers were obtained from BD Biosciences
(Bedford, MA, USA). Recombinant human PDGF-BB (220-BB)
was obtained from R&D Systems, Inc. (Minneapolis, MN, USA).
Human LDL (BT-903) and oxidized LDL (oxLDL) (BT-910)
were purchased from Biomedical Technologies, Inc. (Stoughton,
MA, USA). Antibodies against SM 22α (ab73978), caveolin-3
(ab173575), SM α-actin (ab124964), and myocardin (ab22621)
were obtained from Abcam (Cambridge, MA, USA). Anti-pan-
Akt (2920), anti-phospho S473 Akt1 (9271), and anti-phospho
Erk1/2 (Thr202/Tyr204) (9101) were obtained from Cell Signal-
ing, Inc. (Danvers,MA,USA). Anti-Klf4 (LS-B5641) was obtained
from LifeSpan Biosciences, Inc. (Seattle, WA, USA). Antibod-
ies against caveolin-1 (sc-894), calponin (sc-28545), SRF (sc-
335), SM myosin heavy chain (sc-6956), Erk1/2 (sc-135900), and
phosphorylated Elk-1 (sc-8406) were obtained from Santa Cruz
Biotechnology, Inc. (Dallas, TX, USA). Antibody against β-actin
(A5441) was obtained from Sigma-Aldrich Corp. (St. Louis, MO,
USA). Secondary HRP-conjugated antibodies against mouse and
rabbit antibodies were obtained from Thermo Fisher Scientific,
Inc. (Rockford, IL, USA). LDH cytotoxicity assay kit (10008882)
was purchased from Cayman Chemical Company (Ann Arbor,
MI, USA). Secondary Alexa Fluor® 488 goat anti-mouse IgG
(A11001), Alexa Fluor® 594 goat anti-rabbit IgG (A11012), Alexa
Fluor® 680-conjugated phalloidin (A22286), DAPI (D3571), Pro-
Long® Gold antifade reagent (P36930) and phenol-free, high glu-
cose Dulbecco’s Modified Eagle Medium (DMEM) were obtained
from Life Technologies (Grand Island, NY, USA). BrdU Elisa col-
orimetric kit was obtained from Roche Diagnostics (Indianapolis,
IN, USA).
Cell Culture
A7r5 cells were obtained from the American Type Culture Collec-
tion. Theywere routinely cultured in completemedia [phenol red-
free DMEM supplemented with -glutamine, sodium pyruvate,
penicillin and streptomycin, and 10% fetal bovine serum (FBS)].
Stable Transfection of A7r5 Cells
Cells were infected with retroviral particles containing wild-type
rat caveolin-3 cDNA (14, 21) or empty vector. Two days post-
infection, cells were selected in the presence of puromycin for a
week. After selection, cells were cultured in complete media.
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Confocal Immunofluorescence
A7r5 cells were seeded on coverslips and incubated in com-
plete media. After 3 days in culture, cells were fixed in 2%
paraformaldehyde, permeabilized with Triton X-100, blocked
with 3% BSA in PBS, and incubated with primary antibody for
1 h. Fluorescent-conjugated secondary antibodies were applied to
the coverslips for 30min. When appropriate, cells were washed
with PBS and stained with DAPI and Alexa Fluor® 680-conjugated
phalloidin prior to mounting using ProLong® Gold antifade
reagent. Immunofluorescence images were visualized and cap-
tured using a Zeiss LSM 510 Meta Confocal Laser Scanning
Microscope.
Proliferation Assays
Two types of experiments were performed to evaluate prolifera-
tion. In the first one, cells were seeded in 96-well plates (3,000 cells
per well) with complete media. After 1 day, media was replaced
with DMEM containing 0.1% BSA for 24 h (serum deprivation
media, SDM), and cells were incubated with SDM containing
increasing concentrations of LDL for an additional 48 h. Cells
were then subjected to proliferation measurements using a BrdU
incorporation assay following the manufacturer’s instructions.
In the second experiment, 300,000 cells were seeded in 60-mm
dishes and treated with SDM. After 24 h, 100µg/mL LDL in SDM
was added for 48 h. Cells were then trypsinized and loaded in a
hemocytometer to be counted.
Cell Death/Apoptosis Measurements
Three thousand cells were seeded in 96-well plates and grown in
SDM for 24 h. Cells were then cultured with increasing concentra-
tions of oxLDL for 48 h. LDH activity in the culture supernatant
was determined according to the manufacturer’s instructions.
Wound-Healing Assay
Cell cultures were grown to 100% confluence in six-well plates
using complete media. Once homogeneous monolayers of cells
were obtained, cells were cultured in media supplemented with
1% FBS for 24 h. In each well, a confluent monolayer of cells was
artificially wounded with a micropipette tip. Detached cells were
removed by washing with PBS, and experiments were continued
by incubating cells with 1% FBS in DMEM (control) or 40 ng/mL
PDGF-BB. Wound closure was monitored by comparing digital
photographs of the same region of interest taken at 0- and 24-h
time points. Pictures were analyzed by using the Image J program
developed by Dr. Wayne Rasband (National Institutes of Health,
Bethesda, MD, USA). Additionally, at the end of the experiment,
paraformaldehyde-fixed cells were stained with 0.1% crystal violet
and photographed.
Matrigel Invasion Assay
Twenty-five thousand cells per well were seeded on top of the
insert (upper chamber) placed over a 24-well matrigel invasion
plates (8-µm pore size). The lower chamber was filled with media
containing 0.1% BSA, 1% FBS, or 40 ng/mL PDGF-BB. After 16 h
of culture, non-invading cells were removed from the side where
cells had been seeded, and the side facing the lower chamber was
stained with crystal violet. Pictures of four different fields under a
200microscope magnification were taken to count the number
of stained cells that invaded the matrigel chamber.
Western Blot
Cell protein extraction was conducted by incubating cells with a
RIPA lysis buffer containing phosphatase and protease inhibitors.
Protein concentrations were determined using the BCA protein
assay (Thermo Scientific). Proteins were separated by SDS-PAGE
and then transferred to a nitrocellulose membrane. Ponceau red
staining was used to confirm complete blotting. The membrane
was blocked with 5% non-fat milk or BSA in PBS, washed with
PBS, and incubated with primary antibody diluted in 5% BSA in
PBS-Tween overnight at 4°C. After washing with PBS, the blot was
incubated with HRP-coupled secondary antibody. ECL (Pierce)
was used to develop antibody location via chemiluminescence.
Densitometric analysis was performed using the Image J program.
Statistical Analysis
All data were expressed as mean SD. Data were analyzed using
the Kruskal–Wallis Non-parametric ANOVA test with Dunn’s
Multiple Comparison post-test or the Mann–Whitney test. All
data were processed using INSTAT v. 3.05 (GraphPad Software,
La Jolla, CA, USA). Statistical significance was established at
P< 0.05.
Results
Smooth Muscle Cell Caveolin-3 Expression is
Associated with a Switch Toward a Contractile
Phenotype
Since caveolin-3 protein is lost in cultured cells, we decided
to express caveolin-3 in A7r5 cells using the pBABE retrovirus
expression vector (Figure 1). Expression of caveolin-1 as well as
other markers of SM differentiation was examined.We found that
caveolin-3 expression in A7r5 cells (A7r5-Cav3) was associated
with a robust increase in the expression levels of contractile pro-
tein markers (myocardin, SM myosin heavy chain, SM α-actin)
and a reduction in the levels of protein markers of the synthetic
phenotype (p-Elk-1, KLF4) compared to control-transduced cells
(A7r5-m) (Figure 1A). As expected, SRF showed no difference
in protein expression levels. Interestingly, we observed a clear
switch in the calponin isoforms expressed in these cells. Accord-
ing to Uniprot (Uniprot, http://www.uniprot.org, last accessed
on February 20, 2015), rat h1-calponin (or SM calponin-H1,
Accession # Q08290) and h2-calponin (Accession # D3ZRX9)
have a predicted molecular weight of 33 and 24 kDa, respectively.
As demonstrated in Figure 1A, caveolin-3 expression drastically
downregulated calponin-h2 while calponin-h1 was upregulated.
No change in caveolin-1 or SM 22α expression was detected. Also,
while A7r5 cells presented an ovoid-like shape, A7r5-Cav3 cells
were characterized by a spindle-shaped cellular structure that has
been associated with a contractile morphology.
To further characterize the effect of caveolin-3 on vSMC,
immunofluorescence was conducted to detect caveolin-3, SM α-
actin, and F-actin (Figure 1B). Caveolin-3 not only associated
with the plasma membrane but also appeared to distribute along
stress fiber-like structures. Noticeably, caveolin-3 expression also
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FIGURE 1 | Expression of caveolin-3 promotes the switch to a
contractile phenotype of vSMCs. A7r5 cells were stably transfected
with caveolin-3 cDNA (A7r5-Cav3) or vector alone (A7r5-m) and selected
with puromycin. Stably transfected cells were seeded and collected 48 h
later (80% confluent). (A) Thirty micrograms of total protein was loaded
onto polyacrylamide gels, transferred to nitrocellulose, and incubated with
antibodies against transcription factors relevant for the control of a
contractile phenotype [p-Elk-1, Myocardin, and Krüppel-like Factor 4 (Klf4)]
and protein markers of a contractile phenotype [smooth muscle Myosin
Heavy Chain (SM MHC), smooth muscle 22α (SM 22α), smooth muscle
α-actin (SM α-actin), and calponin (-1 and -2)]. Caveolin-3 protein
detection was performed to confirm its expression and β-actin protein
detection was used as a loading control. (B) Caveolin-3, SM α-actin, and
F-actin were localized by immunofluorescence confocal microscopy. DAPI
staining was used to detect the nucleus. The blue arrow points to stress
fiber-like structures. Scale bar represents 25µm. (C) Co-localization of SM
α-actin and SM 22α was examined by confocal microscopy. DAPI staining
was used to detect the nucleus. Scale bar represents 25µm.
caused SM α-actin to form a well-defined actin network, and
F-actin staining was more pronounced. Conversely, absence of
caveolin-3 was associated with a less bundled and less orga-
nized actin cytoskeleton. Additionally, in another set of experi-
ments, the intracellular localization of SM α-actin and SM 22α
was compared. In Figure 1C, both proteins were found to co-
localize in well-defined structures only when caveolin-3 was
overexpressed. These structures resemble that of an organized
contractile machinery (22).
Caveolin-3 Inhibits vSMC Proliferation Stimulated
by LDL
Earlier studies have indicated that SM phenotype influences
the ability of this cell type to bind and internalize LDL (23).
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We therefore decided to analyze the effect of caveolin-3 in the
regulation of cellular proliferation in the presence of LDL, which
has also been shown to promote vSMC proliferation (24, 25)
(Figure 2A). Initially, the replicating cell index was determined
by BrdU incorporation. This approach showed that exposure of
A7r5-m cells to 10, 50, and 100µg/mL LDL significantly acceler-
ated the progression of vSMC to the S phase compared to A7r5-
Cav3 cells. Also, incubation of cells with 100µg/mL LDL showed
an increased number of viable A7r5-m cells compared to A7r5-
Cav3 cells after 48 h of exposure to LDL (Figure 2A). Previous
studies have shown that the Akt-signaling pathway can regulate
vSMC proliferation (26). To better understand the mechanisms
associated with caveolin-3 inhibition of LDL-induced cell prolif-
eration, we evaluated the activation level of Akt1. As shown in
Figure 2B, LDL-induced phosphorylation of Akt at serine 473was
reduced in the presence of caveolin-3, therefore indicating that
Akt remained inactive in A7r5-Cav3 cells in our 60-min period of
incubation with LDL (Figure 2B). On the contrary, activation of
Erk1/2 reached a peak 5min after LDL treatment of A7r5-m cells,
while a sustained activation of Erk1/2 was observed in A7r5-Cav3
cells.
Caveolin-3 Reduces Cell Motility of vSMC
Another property associated with the SM synthetic phenotype is
the ability of cells to migrate in response to a stimulating factor
such as PDGF (27). In the following experiment, the 2-D migra-
tion response was first examined using a wound-healing assay.
As observed in Figure 3A, A7r5-Cav3 cells hardly responded to
an 8-h period of exposure to PDGF-BB compared to A7r5-m
cells (P< 0.05). This observation was in sharp contrast with the
control cells that were able to fill 40% of the wound after 8 h in the
presence of PDGF. Importantly, no difference was observed under
basal conditions (without stimulus) using cells expressing or not
caveolin-3. Noticeably, while A7r5-m cells presented an ovoid-like
shape, A7r5-Cav3 cells were characterized by a spindle shape that
has been associated with a more differentiated contractile phe-
notype. To gain insight into the role of caveolin-3 in the invasive
capacity of vSMC, A7r5 cells were seeded over amatrigel layer and
PDGF-BB or FBS were used as chemoattractants (Figure 3B). We
show that expression of caveolin-3 prevented the invasion of A7r5
cells when compared to control cells (P< 0.05). Similar levels of
invasion for both types of cells were observed when exposed to
BSA or FBS.
Caveolin-3 Prevents vSMC Cell Death
Previous studies have shown that the importance of vSMC apop-
tosis is directly related to plaque rupture (28, 29). To explore a
potential protective role of caveolin-3, vSMC were exposed to
oxLDL particles to induce cell death. As observed in Figure 4A,
LDH activity in the culture media of A7r5-m cells showed a
significant increase in all treated groups compared to A7r5-Cav3
cells. Adose-dependent curvewas also observed only in the case of
A7r5-m cells. It is inferred that caveolin-3 expression significantly
precluded oxLDL-induced cell death. In support of this hypothe-
sis, A7r5-m cells responded to oxLDL treatment by upregulating
the pro-apoptotic proteins cleaved Caspase-3 and Bax and down-
regulating the anti-apoptotic protein Bcl-2. No changes of this
FIGURE 2 | A7r5-Cav3 cells are resistant to LDL-induced proliferation.
(A) Cells were seeded in complete culture media that was replaced with SDM
24h later. Left panel. Cells in 96-well plates were incubated with 0, 10, 50, or
100µg/mL LDL for an additional period of 48 h. BrdU incorporation was then
performed, and the corresponding ELISA assay was realized according to the
manufacturer’s instructions. Right panel. A7r5 cells (3105 cells in 6-cm
dishes) were incubated with 100µg/mL LDL for 48 h, and cells were then
trypsinized and counted. *P<0.05. (B) Cells were seeded in 6-cm dishes in
complete media, cultured in SDM for 24 h, and then exposed to 100µg/mL
LDL for 5, 15, 30, or 60min. After the corresponding exposure time, cells
were collected and lysed. Thirty micrograms of total protein was loaded onto
polyacrylamide gels, transferred to nitrocellulose, and incubated with
antibodies against phosphorylated Akt1, total Akt, phosphorylated Erk 1/2,
total Erk 1/2, or caveolin-3. Primary antibodies were detected with
HRP-conjugated secondary antibodies. Relative levels of phosphorylated Akt,
Erk1/2 were quantified by densitometry and expressed as the percentage of
non-LDL treated A7r5-m cells (control group).
type were detected in A7r5-Cav3 cells (Figure 4B). Interestingly,
Bcl-2 expression in A7r5-Cav3 cells was even increased under
basal conditions.
Discussion
vSMCs typically regulate the contraction of blood vessels, and
their function is finely regulated by signaling molecules sent by
endothelial cells (30). The vSMC cell state is regulated by key co-
transcription factors such as Klf4, Elk-1, and myocardin. These
co-transcription factors bind to SRF to regulate the transcription
of genes encoding proteins involved in the contractionmachinery
(6, 7). Klf4 is upregulated in response to vascular injury (syn-
thetic phenotype) and represses the expression of vSMC genes
(10). Active Elk-1 (phosphorylated Elk-1) has been shown to
regulate the expression of c-fos during stimulated DNA synthe-
sis in vSMC (31) and displace myocardin from SRF by motif
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FIGURE 3 | A7r5-Cav3 cells display reduced migratory response to
PDGF. (A) 4105 cells were seeded in six-well plates; complete media was
replaced with SDM for 24 h. A 100% confluent cell culture was submitted to a
wound with a pipette tip and washed, and 50 ng/mL PDGF was added. After
8 h of culture, cells were washed, fixed, and stained with crystal violet. Pictures
were taken at 0- and 8-h time points. Left panel. Representative pictures of
stained fields are shown at the end of the experiment of cells treated (+) or not
( ) with PDGF. Scale bar represents 0.1mm. Right panel. Graph represents the
percentage of area cell-free (% of wound closure) remaining after 8 h of PDGF
exposure (+) or vehicle alone ( ) for three independent experiments. *P<0.05.
(B) In an invasion chamber, 25103 cells were seeded over matrigel in the
upper chamber with medium containing 0.1% BSA. Medium containing 0.5%
BSA, 1% FBS, or 50 ng/mL PDGF was added to the lower chamber. After 16 h
of culture, the upper chamber was removed, cleaned, and stained with crystal
violet. Upper panel shows representative images of fields viewed under the
microscope (200). Lower panel shows the quantification of the number of
cells per field. White and black bars represent A7r5-m and A7r5-Cav3 cells,
respectively. *P<0.05.
competition, enhancing repression of vSMC genes (6, 32). On
the other hand, myocardin has been shown to coordinate the
expression of genes that promote the vSMC contractile pheno-
type (6, 11). It can be inferred that the vascular SM cell type
is not terminally differentiated and can switch between the two
phenotypes. This idea is supported by the fact that cells obtained
from freshly prepared cultures of adult aortic vSMC turn on genes
associated with the synthetic phenotype while those associated
with the contractile one are turned off (33). In the present work,
caveolin-3-mediated changes in the expression of these key co-
transcription factors were identified. It was observed that expres-
sion of caveolin-3 caused a downregulation of active Elk-1 and
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FIGURE 4 | Caveolin-3 prevents oxidized LDL-induced cell death. Cells
were seeded in complete media, and, 24 h later, media was replaced with
SDM containing oxidized LDL (oxLDL). (A) 3103 cells were seeded in
96-well plates and exposed to increasing concentrations of oxLDL for 24 h.
LDH activity in the culture media was determined according to the
manufacturer’s instructions. A graph displaying the average of three
experiments is shown. *P<0.05. (B) Western blot analysis was performed to
detect the levels of cleaved caspase-3 (Cl-caspase-3), Bax, Bcl-2, caveolin-3,
and total Akt from cells treated with 50µg/mL oxLDL for 24 h. Relative levels
of Cl-caspase-3, Bax, and Bcl-2 were quantified by densitometry and
expressed as the percentage of non-oxLDL treated A7r5-m cells (control
group).
Klf4 and an upregulation of myocardin, while no changes in
SRF were detected (Figure 1). Furthermore, caveolin-3 was able
to alter the synthetic phenotype and promote the acquisition of
contractile properties. In addition, expression of caveolin-3 led
to a diminished response to proliferative and chemoattractant
stimulus. This effect of caveolin-3 is in line with the observation
that caveolin-3, but not caveolin-1, was downregulated when the
contractile-to-synthetic transition occurred in vSMC (19). These
findings are also consistent with the previously demonstrated role
of caveolin-3 in skeletal myoblast differentiation (14).
Caveolin-3 and the Regulation of a Contractile
Phenotype
In agreement with the upregulation of myocardin observed in
caveolin-3-expressing cells, an upregulation of contractile protein
markers (SMMHC and SM α-actin) was detected. Importantly, a
clear switch in calponin isoforms expression was detected where
the h2-calponin and h1-calponin were down and upregulated in
caveolin-3-expressing vSMCs, respectively. The observed reduc-
tion in h2-calponin may be associated with its role in inhibiting
cellular proliferation while h1-calponin is expressed in quiescent
differentiated vSMCs (34). These molecular changes observed
with caveolin-3 expression were also evident by immunofluores-
cence analysis where SM α-actin expression was increased and
a cytoskeletal reorganization accompanied the formation of a
more clearly defined F-actin network associated with a contractile
phenotype.
Moreover, even if caveolin-3 did not affect SM 22α protein
levels (Figure 1A), caveolin-3 induced a clear reorganization of
the distribution of SM 22α, which associated with the contractile
machinery and co-localized with SM α-actin (Figure 1C). The
upregulation of SMα-actin and its observed intracellular distribu-
tion pattern suggest an enhanced contractile activity, as previously
described in other cell types (22). Interestingly, caveolin-3 was
associated with the plasma membrane and stress fiber-like struc-
tures within the cells. This finding suggests that caveolin-3 may
have two distinct functions in vSMC. Caveolin-3 may regulate
signaling pathways at the plasma membrane levels but may also
associatewith the cytosketelal network, thereby directly regulating
vSMC contraction.
Previous studies have shown that myocardin expression is reg-
ulated by intracellular calcium signaling in vSMCs (35). Since
caveolin-3 plays an important role in the regulation of calcium
metabolism (36), our data suggest that caveolin-3 may regulate
calciummetabolism to promotemyocardin upregulation and, as a
consequence, increases the expression levels of contractile mark-
ers (37). Additionally, miR-145 and miR-143 transcription has
been shown to be regulated by myocardin, and these microRNAs
have also been demonstrated to play key roles in the regulation of
SM cell phenotype (38). Importantly, reduction of KLF4 activity
has been observed upon induction of miR-145 and miR-143.
Therefore, the present study suggests that caveolin-3 may be a key
regulation of vSMC function.
Caveolin-3 and the Regulation of a Synthetic
Phenotype
In accordance with the quiescent contractile phenotype promoted
by caveolin-3, a diminished cellular proliferation response was
observed upon LDL treatment (Figures 2A,B). Previous stud-
ies have shown that LDL activates proliferative signals via the
ROS/Erk-signaling pathway in vSMCs (24). In the present study,
we also observed that LDL-induced activation of Akt1 was pre-
cluded by caveolin-3 expression. vSMC Akt1 signaling is essential
for proliferation (39) and represses myocardin promoter activ-
ity (40). In that case, inhibition of the Akt1 signaling path-
way by caveolin-3 may therefore be associated with increased
myocardin activity. Remarkably, a sustained activation of Erk1/2
was observed in cells overexpressing caveolin-3 upon LDL stimu-
lation. This finding is in agreement with previous studies showing
that constitutively active Erk1/2 may be related to an antipro-
liferative effect and a potential role in the regulation of cellular
differentiation (41–43). Yang et al. (40) have postulated that Spry1
and Spry4 can modulate FGFR and EGFR signaling in vSMC:
while Spry4 inhibits both Erk1/2 and Akt pathway activation,
Spry1 enhances Akt activation. Importantly, Cabrita et al. (44)
have reported that Spry1 and Spry4 canphysically interactwith the
C-terminus of caveolin-1 and that Spry1 and caveolin-1 coopera-
tively inhibit FGF2-mediated signaling. In the current study, LDL
was used to induce cellular proliferation, and we expected both
Akt and Erk1/2 signaling pathways to be inhibited by caveolin-3.
However, caveolin-3 expression only inhibited the Akt pathway
while a sustained activation of the Erk1/2 pathway was observed.
Based on the aforementioned studies, caveolin-3may bind/inhibit
Spry1 and Spry4, causing inhibition of the Akt-signaling pathway,
thereby allowing a prolonged activation of Erk1/2 mediated by
LDL. Alternatively, caveolin-1 and caveolin-3 may be associated
with distinct caveolae and bind different proteins, which may
allow for a differential regulation of the Erk1/2 and Akt-signaling
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pathways. The opposite effects of caveolin-3 on Erk1/2 and Akt
activation suggest that caveolin-3may be an important modulator
of signaling pathways triggered by LDL.
Cellular migration is another relevant feature of the vSMC
synthetic phenotype. Previous studies have shown that PDGF
induces migration of vSMC (27). Our study clearly indicates that
this pathway is remarkably inhibited in caveolin-3-expressing cells
(Figure 3). Moreover, PDGF-stimulated matrigel invasion was
also inhibited by caveolin-3. Inhibition of Akt1 phosphorylation
by caveolin-3 (Figure 2B) could also explain the low migratory
response since this kinase has been shown to play an important
role in the regulation of cell migration (39).
Regulation of Caveolin-3 Transcription and
Expression
In cultured vSMC, caveolin-3 is not regulated at the post-
translation level but most likely at the transcriptional level. In
support of this hypothesis, we have not observed any change in
caveolin-3 protein expression after 20 passages in our model sys-
tem. Our current findings indicate that transcription factors such
as SRF, regulated bymyocardin, may be essential for the transcrip-
tion of the CAV-3 gene, and that their downregulation or inhibi-
tion upon phenotyping switch may lead to reduced transcription
of the CAV-3 gene. Little is known about the mechanism regulat-
ing transcription of the caveolin-3 gene in vSMCs. However, in
skeletal muscles, previous studies have shown that transcription
of the CAV-3 gene is enhanced by transcription factors such as
TEAD4 (45), myogenin (46), or RORα (47). Interestingly, recent
studies byMartínez-Moren et al. (48) have shown that exposure of
C2C12 myoblasts to nitric oxide (NO) is associated with reduced
transcription of the Cav-3 gene. In that case, it was shown that S-
nitrosylation of themuscular transcription factor myogenin led to
a reduced myogenin transcriptional activity, which was respon-
sible for the decrease in caveolin-3 mRNA levels. Transposed to
the vasculature, this finding may suggest that NO production by
endothelial cells could also directly affect vSMC caveolin-3 levels
by inhibiting myocardin activity and therefore regulate vascular
relaxation. Accordingly, reduced caveolin-3 protein levels may
be associated with increased relaxation of the vasculature. Since
expression of caveolin-3 in vSMC increases the levels of endoge-
nous myocardin (Figure 1A), a reciprocal regulation of the two
proteins may be critical to ensure a proper contractile phenotype.
Role of Caveolin-3 in the Development of
Atherosclerosis
The present study provides new evidence suggesting that caveolin-
3 may regulate arterial SM cell phenotype. Our data suggest that
caveolin-3 may also be an important player in the regulation of
SM cell function in vivo and that caveolin-3 may also play a key
role in the development of atherosclerosis. Caveolin-3 may be one
of the first proteins to be downregulated before migrating into the
arterial intima, and its loss may, via its ability to regulate specific
signaling cascades, accelerate the switch between contractile and
synthetic phenotypes. Under these conditions, caveolin-3 may
have an anti-atherogenic role and reduce migration and prolifer-
ation of vSMC. Signals that may regulate caveolin-3 protein levels
in arterial vSMCs may include oxidized lipoproteins or cytokines.
Loss of caveolin-3 may trigger a downregulation of myocardin,
which has been shown to play a critical role in the regulation
of essential properties associated with a contractile and non-
inflammatory phenotype (49). Our data showing that caveolin-
3 expression is reduced upon atheroma formation in Apoe / 
mouse aorta (Frank et al., unpublished results) are consistent with
a role for caveolin-3 in the maintenance of vSMC contractile
phenotype.
Intimal vSMCs exposed to oxLDL have also been shown to be
susceptible to apoptosis (50, 51). As shown in Figure 4A, upon
oxLDL exposure, A7r5-m cells underwent cell death by upregu-
lating the pro-apoptotic proteins Bax and cleaved-caspase-3 and
downregulating the anti-apoptotic protein Bcl-2 (Figure 4B). By
contrast, caveolin-3 expression was associated with resistance to
apoptosis in A7r5-Cav3 cells. The absence of effects of oxLDL
in the presence of caveolin-3 may be due to the lack of efficient
internalization of lipoproteins possibly due to reduced levels of
scavenger receptors, such as CD36, OLR1 (aka, LOX-1), or SR-AI.
This hypothesis is consistent with the observation that synthetic
vSMC can form foam cells in a manner similar to macrophages
(52). These data suggest that caveolin-3 expressionmay allow cells
to maintain a contractile phenotype and reduce the deleterious
effects of oxLDL. OxLDL can induce apoptosis by modulating
Bax/Bcl-2 through its receptor OLR1 in vSMCs (28). Previous
studies have shown that OLR1 is palmitoylated and uses the
caveolae/raft-dependent endocytosis pathway to internalize its
ligand (53, 54). Since we observed a minimal co-localization of
caveolin-1 and caveolin-3 in A7r5-Cav3 cells (data not shown),
OLR1 may be re-locating outside of caveolin-1-rich caveolae to
caveolin-3-rich caveolae andmay, as a consequence, inhibit down-
stream signaling pathways induced by oxLDL in A7r5-Cav3 cells.
Atherosclerosis is characterized by increased vSMC migration
and proliferation in the intima during lesion formation. There-
fore, a better understanding of the factors regulating caveolin-
3 transcription may allow the development of new treatments
that could control vSMC proliferation and migration, and there-
fore, atheroma formation. In addition, since vSMCs apoptosis
and extracellular matrix protein synthesis play essential roles in
the regulation of the vulnerable plaque formation (55), these
treatments would also be applicable to prevent plaque rupture in
patients at high risk for coronary artery diseases.
In conclusion, caveolin-3 promotes vSMC contractile pheno-
type and reduces cell proliferation and migration. Our findings
demonstrate that caveolin-3 is a key protein that may be down-
regulated during atherosclerosis development or restenosis to
promote vSMC dedifferentiation.
Acknowledgments
PGF was supported by grants from the Jane Barsumian/Mary
Lyons Trust and the W. W. Smith Charitable Trust and is
currently supported by a grant from the LIPIDS ARD2020-
Biopharmaceuticals project (Région Centre, France). JLGP is a
researcher supported by Le Studium (Région Centre, France). The
Bioimaging Shared Resource of the Sidney Kimmel Cancer Center
at Thomas Jefferson University (NCI 5 P30 CA-56036) was used
in this study.
Frontiers in Cardiovascular Medicine | www.frontiersin.org June 2015 | Volume 2 | Article 278
Gutierrez-Pajares et al. Caveolin-3 and vascular smooth muscle
References
1. Metz RP, Patterson JL, Wilson E. Vascular smooth muscle cells: isolation,
culture, and characterization. Methods Mol Biol (2012) 843:169–76. doi:10.
1007/978-1-61779-523-7_16
2. Vukovic I, Arsenijevic N, Lackovic V, Todorovic V. The origin and differen-
tiation potential of smooth muscle cells in coronary atherosclerosis. Exp Clin
Cardiol (2006) 11(2):123–8.
3. Mosse PR, Campbell GR, Campbell JH. Smooth muscle phenotypic expression
in human carotid arteries. II. Atherosclerosis-free diffuse intimal thickenings
compared with the media. Arteriosclerosis (1986) 6(6):664–9. doi:10.1161/01.
ATV.6.6.664
4. Schwartz SM. Smoothmusclemigration in atherosclerosis and restenosis. J Clin
Invest (1997) 100(11 Suppl):S87–9.
5. Wang X, Hu G, Betts C, Harmon EY, Keller RS, Van De Water L, et al.
Transforming growth factor-beta1-induced transcript 1 protein, a novel marker
for smooth muscle contractile phenotype, is regulated by serum response
factor/myocardin protein. J Biol Chem (2011) 286(48):41589–99. doi:10.1074/
jbc.M111.250878
6. Wang Z, Wang DZ, Hockemeyer D, McAnally J, Nordheim A, Olson
EN. Myocardin and ternary complex factors compete for SRF to control
smooth muscle gene expression. Nature (2004) 428(6979):185–9. doi:10.1038/
nature02382
7. Zhou J, Hu G, Herring BP. Smooth muscle-specific genes are differentially
sensitive to inhibition by Elk-1. Mol Cell Biol (2005) 25(22):9874–85. doi:10.
1128/MCB.25.22.9874-9885.2005
8. Pidkovka NA, Cherepanova OA, Yoshida T, Alexander MR, Deaton RA,
Thomas JA, et al. Oxidized phospholipids induce phenotypic switching of vas-
cular smooth muscle cells in vivo and in vitro. Circ Res (2007) 101(8):792–801.
doi:10.1161/CIRCRESAHA.107.152736
9. Davis-Dusenbery BN, Chan MC, Reno KE, Weisman AS, Layne MD, Lagna
G, et al. Down-regulation of Kruppel-like factor-4 (KLF4) by MICRORNA-
143/145 is critical for modulation of vascular smooth muscle cell phenotype
by transforming growth factor-{beta} and bone morphogenetic protein 4. J Biol
Chem (2011) 286(32):28097–110. doi:10.1074/jbc.M111.236950
10. Liu Y, Sinha S, McDonald OG, Shang Y, Hoofnagle MH, Owens GK. Kruppel-
like factor 4 abrogates myocardin-induced activation of smooth muscle gene
expression. J Biol Chem (2005) 280(10):9719–27. doi:10.1074/jbc.M412862200
11. Parmacek MS. Myocardin: dominant driver of the smooth muscle cell contrac-
tile phenotype.Arterioscler ThrombVasc Biol (2008) 28(8):1416–7. doi:10.1161/
ATVBAHA.108.168930
12. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the
initiation and early progression of atherosclerosis.Arterioscler ThrombVasc Biol
(2008) 28(5):812–9. doi:10.1161/ATVBAHA.107.159327
13. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal
physiology. Pharmacol Rev (2002) 54(3):431–67. doi:10.1124/pr.54.3.431
14. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, et al. Expression of
caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a compo-
nent of the sarcolemma and co-fractionates with dystrophin and dystrophin-
associated glycoproteins. J Biol Chem (1996) 271(25):15160–5. doi:10.1074/jbc.
271.25.15160
15. Woodman SE, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, et al.
Urogenital alterations in aged male caveolin-1 knockout mice. J Urol (2004)
171(2 Pt 1):950–7. doi:10.1097/01.ju.0000105102.72295.b8
16. WayM, Parton R. M-caveolin, a muscle-specific caveolin-related protein. FEBS
Lett (1995) 376:108–12. doi:10.1016/0014-5793(95)01256-7
17. Segal SS, Brett SE, Sessa WC. Codistribution of NOS and caveolin throughout
peripheral vasculature and skeletal muscle of hamsters. Am J Physiol (1999)
277(3 Pt 2):H1167–77.
18. Shanahan CM, Weissberg PL. Smooth muscle cell heterogeneity. Arterioscler
Thromb Vasc Biol (1998) 18:333–8. doi:10.1161/01.ATV.18.3.333
19. Doyle DD, Upshaw-Earley J, Bell E, Palfrey HC. Expression of caveolin-3
in rat aortic vascular smooth muscle cells is determined by developmen-
tal state. Biochem Biophys Res Commun (2003) 304(1):22–5. doi:10.1016/
S0006-291X(03)00528-X
20. Gittenberger-de Groot AC, DeRuiter MC, Bergwerff M, Poelmann RE. Smooth
muscle cell origin and its relation to heterogeneity in development and
disease. Arterioscler Thromb Vasc Biol (1999) 19(7):1589–94. doi:10.1161/01.
ATV.19.7.1589
21. Capozza F, Cohen AW, Cheung MW, Sotgia F, Schubert W, Battista M, et al.
Muscle-specific interaction of caveolin isoforms: differential complex forma-
tion between caveolins in fibroblastic vs. muscle cells. Am J Physiol Cell Physiol
(2005) 288(3):C677–91. doi:10.1152/ajpcell.00232.2004
22. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth
muscle actin expression upregulates fibroblast contractile activity.Mol Biol Cell
(2001) 12(9):2730–41. doi:10.1091/mbc.12.9.2730
23. Campbell JH, Reardon MF, Campbell GR, Nestel PJ. Metabolism of athero-
genic lipoproteins by smooth muscle cells of different phenotype in culture.
Arteriosclerosis (1985) 5(4):318–28. doi:10.1161/01.ATV.5.4.318
24. Locher R, Brandes RP, Vetter W, Barton M. Native LDL induces proliferation
of human vascular smooth muscle cells via redox-mediated activation of ERK
1/2 mitogen-activated protein kinases. Hypertension (2002) 39(2 Pt 2):645–50.
doi:10.1161/hy0202.103473
25. Heo KS, Ryoo SW, Kim L, NamM, Baek ST, Lee H, et al. Cl- channel is essential
for LDL-induced cell proliferation via the activation of Erk1/2 and PI3k/Akt and
the upregulation of Egr-1 in human aortic smoothmuscle cells.Mol Cells (2008)
26(5):468–73.
26. Stabile E, Zhou YF, Saji M, Castagna M, Shou M, Kinnaird TD, et al. Akt
controls vascular smooth muscle cell proliferation in vitro and in vivo by delay-
ingG1/S exit.Circ Res (2003) 93(11):1059–65. doi:10.1161/01.RES.0000105086.
31909.1B
27. Garcia-Olivas R, Vilaro S, Reina M, Castel S. PDGF-stimulated cell prolifer-
ation and migration of human arterial smooth muscle cells. Colocalization
of PDGF isoforms with glycosaminoglycans. Int J Biochem Cell Biol (2007)
39(10):1915–29. doi:10.1016/j.biocel.2007.05.011
28. Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K,
et al. Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL
receptor-1 in vascular smoothmuscle cells.Arterioscler ThrombVasc Biol (2001)
21(6):955–60. doi:10.1161/01.ATV.21.6.955
29. Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of
atherosclerosis. Acta Med Indones (2007) 39(2):86–93.
30. Ge D, Meng N, Su L, Zhang Y, Zhang SL, Miao JY, et al. Human vascular
endothelial cells reduce sphingosylphosphorylcholine-induced smooth muscle
cell contraction in co-culture system through integrin beta4 and Fyn. Acta
Pharmacol Sin (2012) 33(1):57–65. doi:10.1038/aps.2011.142
31. Xi XP, Graf K, Goetze S, Hsueh WA, Law RE. Inhibition of MAP kinase blocks
insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-
1 in vascular smooth muscle cells. FEBS Lett (1997) 417(3):283–6. doi:10.1016/
S0014-5793(97)01303-3
32. Yoshida T, Gan Q, Owens GK. Kruppel-like factor 4, Elk-1, and histone
deacetylases cooperatively suppress smooth muscle cell differentiation mark-
ers in response to oxidized phospholipids. Am J Physiol Cell Physiol (2008)
295(5):C1175–82. doi:10.1152/ajpcell.00288.2008
33. Sprinkle DJ, Subbiah MT. Studies on aorta during development. I. Fetal rabbit
aorta under ex vivo and in vitro conditions: rapid changes in smooth muscle
cell phenotype, cell proliferation and cholesterol content with organ culture.
Atherosclerosis (1987) 67(1):57–69. doi:10.1016/0021-9150(87)90265-6
34. Hossain MM, Hwang DY, Huang QQ, Sasaki Y, Jin JP. Developmentally reg-
ulated expression of calponin isoforms and the effect of h2-calponin on cell
proliferation. Am J Physiol Cell Physiol (2003) 284(1):C156–67. doi:10.1152/
ajpcell.00233.2002
35. Pagiatakis C, Gordon JW, Ehyai S, McDermott JC. A novel RhoA/ROCK-
CPI-17-MEF2C signaling pathway regulates vascular smooth muscle cell gene
expression. J Biol Chem (2012) 287(11):8361–70. doi:10.1074/jbc.M111.286203
36. Weiss N, Couchoux H, Legrand C, Berthier C, Allard B, Jacquemond V.
Expression of the muscular dystrophy-associated caveolin-3(P104L) mutant in
adult mouse skeletal muscle specifically alters the Ca(2+) channel function of
the dihydropyridine receptor. Pflugers Arch (2008) 457(2):361–75. doi:10.1007/
s00424-008-0528-z
37. Du KL, Ip HS, Li J, ChenM, Dandre F, YuW, et al. Myocardin is a critical serum
response factor cofactor in the transcriptional program regulating smooth
muscle cell differentiation. Mol Cell Biol (2003) 23(7):2425–37. doi:10.1128/
MCB.23.7.2425-2437.2003
38. Cordes KR, Sheehy NT,White MP, Berry EC, Morton SU, Muth AN, et al. miR-
145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature (2009)
460(7256):705–10. doi:10.1038/nature08195
39. Fernandez-Hernando C, Jozsef L, Jenkins D, Di Lorenzo A, SessaWC. Absence
ofAkt1 reduces vascular smoothmuscle cellmigration and survival and induces
Frontiers in Cardiovascular Medicine | www.frontiersin.org June 2015 | Volume 2 | Article 279
Gutierrez-Pajares et al. Caveolin-3 and vascular smooth muscle
features of plaque vulnerability and cardiac dysfunction during atherosclerosis.
Arterioscler Thromb Vasc Biol (2009) 29(12):2033–40. doi:10.1161/ATVBAHA.
109.196394
40. Yang X, Gong Y, Tang Y, Li H, He Q, Gower L, et al. Spry1 and
Spry4 differentially regulate human aortic smooth muscle cell phenotype via
Akt/FoxO/myocardin signaling. PLoS One (2013) 8(3):e58746. doi:10.1371/
journal.pone.0058746
41. Alldridge LC, Bryant CE. Annexin 1 regulates cell proliferation by disruption
of cell morphology and inhibition of cyclin D1 expression through sustained
activation of the ERK1/2 MAPK signal. Exp Cell Res (2003) 290(1):93–107.
doi:10.1016/S0014-4827(03)00310-0
42. Bourgin C, Bourette R, Mouchiroud G, Arnaud S. Expression of Mona (mono-
cytic adapter) in myeloid progenitor cells results in increased and prolonged
MAP kinase activation upon macrophage colony-stimulating factor stimula-
tion. FEBS Lett (2000) 480(2–3):113–7. doi:10.1016/S0014-5793(00)01906-2
43. Harada T, Morooka T, Ogawa S, Nishida E. ERK induces p35, a neuron-specific
activator of Cdk5, through induction of Egr1. Nat Cell Biol (2001) 3(5):453–9.
doi:10.1038/35074516
44. Cabrita MA, Jaggi F, Widjaja SP, Christofori G. A functional interaction
between sprouty proteins and caveolin-1. J Biol Chem (2006) 281(39):29201–12.
doi:10.1074/jbc.M603921200
45. Benhaddou A, Keime C, Ye T, Morlon A, Michel I, Jost B, et al. Transcription
factor TEAD4 regulates expression of myogenin and the unfolded protein
response genes during C2C12 cell differentiation. Cell Death Differ (2012)
19(2):220–31. doi:10.1038/cdd.2011.87
46. Biederer CH, Ries SJ, Moser M, Florio M, Israel MA, McCormick F, et al. The
basic helix-loop-helix transcription factors myogenin and Id2 mediate specific
induction of caveolin-3 gene expression during embryonic development. J Biol
Chem (2000) 275(34):26245–51. doi:10.1074/jbc.M001430200
47. Lau P, Nixon SJ, Parton RG, Muscat GE. RORalpha regulates the expression of
genes involved in lipid homeostasis in skeletalmuscle cells: caveolin-3 andCPT-
1 are direct targets of ROR. J Biol Chem (2004) 279(35):36828–40. doi:10.1074/
jbc.M404927200
48. Martinez-Moreno M, Martinez-Ruiz A, Alvarez-Barrientos A, Gavilanes F,
Lamas S, Rodriguez-Crespo I. Nitric oxide down-regulates caveolin-3 levels
through the interaction with myogenin, its transcription factor. J Biol Chem
(2007) 282(32):23044–54. doi:10.1074/jbc.M610751200
49. Ackers-Johnson M, Talasila A, Sage AP, Long X, Bot I, Morrell NW, et al.
Myocardin regulates vascular smooth muscle cell inflammatory activation
and disease. Arterioscler Thromb Vasc Biol (2015) 35(4):817–28. doi:10.1161/
ATVBAHA.114.305218
50. Thorne SA, Abbot SE, Stevens CR, Winyard PG, Mills PG, Blake DR. Modified
low density lipoprotein and cytokines mediate monocyte adhesion to smooth
muscle cells.Atherosclerosis (1996) 127(2):167–76. doi:10.1016/S0021-9150(96)
05948-5
51. Okura Y, Brink M, Itabe H, Scheidegger KJ, Kalangos A, Delafontaine P.
Oxidized low-density lipoprotein is associated with apoptosis of vascular
smooth muscle cells in human atherosclerotic plaques. Circulation (2000)
102(22):2680–6. doi:10.1161/01.CIR.102.22.2680
52. Chaabane C, Coen M, Bochaton-Piallat ML. Smooth muscle cell pheno-
typic switch: implications for foam cell formation. Curr Opin Lipidol (2014)
25(5):374–9. doi:10.1097/MOL.0000000000000113
53. Kumano-Kuramochi M, Xie Q, Kajiwara S, Komba S, Minowa T, Machida S.
Lectin-like oxidized LDL receptor-1 is palmitoylated and internalizes ligands
via caveolae/raft-dependent endocytosis. Biochem Biophys Res Commun (2013)
434(3):594–9. doi:10.1016/j.bbrc.2013.03.120
54. Sun SW, Zu XY, Tuo QH, Chen LX, Lei XY, Li K, et al. Caveolae and caveolin-
1 mediate endocytosis and transcytosis of oxidized low density lipoprotein in
endothelial cells. Acta Pharmacol Sin (2010) 31(10):1336–42. doi:10.1038/aps.
2010.87
55. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability
and rupture. Arterioscler Thromb Vasc Biol (2007) 27(1):15–26. doi:10.1161/01.
ATV.0000251503.35795.4f
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Gutierrez-Pajares, Iturrieta, Dulam, Wang, Pavlides, Malacari,
Lisanti and Frank. This is an open-access article distributed under the terms of the
Creative CommonsAttribution License (CCBY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Cardiovascular Medicine | www.frontiersin.org June 2015 | Volume 2 | Article 2710
